Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Dec:2:112-115.
doi: 10.1016/j.pvr.2016.05.004. Epub 2016 Jun 1.

Need for expanded HPV genotyping for cervical screening

Jack Cuzick  1 , Cosette Wheeler  2
Affiliations
Editorial

Need for expanded HPV genotyping for cervical screening

Jack Cuzick et al. Papillomavirus Res. 2016 Dec.

Abstract

The focus for HPV genotyping has largely been on types 16 and 18, based on their high prevalence in cervix cancer. However screening is focussed on the detection of high grade precursor lesions (CIN3 and CIN2), where other types have a greater role. While HPV16 retains its high predictive value in this context, HPV31 and especially HPV33 emerge as important types with higher positive predictive values (PPVs) than HPV18. Additionally full typing indicates that types 39, 56, 59 and 68 have much lower PPVs than types 16, 18, 31, 33, 35, 45, 51, 52 and 58 and they should be considered as 'intermediate risk' types, whereas type 66 should not be treated as having an increased risk. Available data are summarized to support this view.

PubMed Disclaimer

Comment on

References

    1. Wright T.C., Stoler M.H., Behrens C.M., Sharma A., Zhang G., Wright T.L. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 2015;136(2):189–197. - PubMed
    1. Wright T.C., Jr, Stoler M.H., Sharma A., Zhang G., Behrens C., Wright T.L., ATHENA Study Group Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am. J. Clin. Pathol. 2011;136(4):578–586. - PubMed
    1. Monsonego J., Cox J.T., Behrens C., Sandri M., Franco E.L., Yap P.S., Huh W. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol. Oncol. 2015;137(1):47–54. - PubMed
    1. Cuzick J., Ho L., Terry G., Kleeman M., Giddings M., Austin J., Cadman L., Ashdown-Barr L., Costa M.J., Szarewski A. Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J. Clin. Virol. 2014;60(1):44–49. - PMC - PubMed
    1. Kovacic M.B., Castle P.E., Herrero R., Schiffman M., Sherman M.E., Wacholder S., Rodriguez A.C., Hutchinson M.L., Bratti M.C., Hildesheim A., Morales J., Alfaro M., Burk R.D. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006;66(20):10112–10119. - PubMed